Cargando…
The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses
Background: Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), such as cetuximab and nimotuzumab have been used in the treatment of nasopharyngeal carcinoma (NPC), yet their efficacy and safety are undetermined. Materials and Methods: We performed two meta-analyses based o...
Autores principales: | Peng, Liang, Liu, Ze-Long, Xu, Cheng, Tang, Ling-Long, Liu, Xu, Lin, Ai-Hua, Sun, Ying, Chen, Yu-Pei, Ma, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277641/ https://www.ncbi.nlm.nih.gov/pubmed/30519357 http://dx.doi.org/10.7150/jca.27611 |
Ejemplares similares
-
Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021) -
Anti‐epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: Peng, Hao, et al.
Publicado: (2018) -
Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020) -
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
por: Niu, Xiaoshuang, et al.
Publicado: (2023) -
All anti-CD20 monoclonal antibodies have similar efficacy and safety risks:
Yes
por: Cree, Bruce AC
Publicado: (2022)